Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months.
about
Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virusImmunization of preterm infantsIgG placental transfer in healthy and pathological pregnanciesComparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in miceDesign of a small-molecule entry inhibitor with activity against primary measles virus strains.Bacterial lysates improve the protective antibody response against respiratory viruses through Toll-like receptor 4.A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measlesProtective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice.Subacute sclerosing panencephalitis in papua new guinean children: the cost of continuing inadequate measles vaccine coverage.Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responsesLow titers of measles antibody in mothers whose infants suffered from measles before eligible age for measles vaccinationVaccination in the neonatal period and early infancy.Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles.Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review.Targeting regulatory T cells to improve vaccine immunogenicity in early life.Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies.Immunity to RSV in Early-Life.Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.Influence of maternal antibodies on neonatal immunization against respiratory viruses.Can successful vaccines teach us how to induce efficient protective immune responses?Induction of type I interferon secretion through recombinant Newcastle disease virus expressing measles virus hemagglutinin stimulates antibody secretion in the presence of maternal antibodiesRole of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys.Synergistic induction of interferon α through TLR-3 and TLR-9 agonists stimulates immune responses against measles virus in neonatal cotton ratsAttenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats.Biological feasibility of measles eradicationInsights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies.Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneouslyMeasles outbreak in South of iran, where vaccine coverage was high: a case-series studyConsistency of HLA associations between two independent measles vaccine cohorts: a replication studyA correlation of measles specific antibodies and the number of plasmacytoid dendritic cells is observed after measles vaccination in 9 month old infants.Immunisation of premature infants.Acquisition of maternal antibodies both from the placenta and by lactation protects mouse offspring from Yersinia pestis challenge.Lessons learned and applied: what the 20th century vaccine experience can teach us about vaccines in the 21st centuryDose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of ageModelling the first dose of measles vaccination: the role of maternal immunity, demographic factors, and delivery systemsPoor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins.Age-appropriate vaccination against measles and DPT-3 in India - closing the gapsProtective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial.Age-related changes in serological susceptibility patterns to measles: results from a seroepidemiological study in Dongguan, China
P2860
Q24658311-5105DCFB-AFEF-4588-843E-C2D079F2DFD0Q26796295-E82EE7FE-C070-4B27-975A-61FA3B322F07Q27025979-95313781-7621-4674-AE94-4E9B3E0FDCA8Q28752489-CAAA158E-2181-46AB-9579-413045AC65C2Q33222430-1B1927BF-6FD5-4AF8-97D9-153B3677AE32Q33723524-076C3C5E-D55D-4C55-9EBC-1A811A711149Q33769306-451FBE49-67A4-46CD-834A-76F17B05791DQ33792707-FEA3B9DB-ACF9-4822-AE66-6CAE119E06A5Q33796521-3D3EEB12-FB38-4898-B81F-06DAC127C7FAQ33808891-178D973A-F913-42C6-8FE1-86D2A4FF2141Q33870082-F5ECA81E-ECE8-462E-B569-DE574A065C53Q33891058-37E7A7FB-B4DA-43DD-8CC6-A3CC9DD39BF4Q33920185-B5CEBD3E-C616-4FEE-84BD-5B296FA631D0Q33982860-C601726F-CA34-45C4-BEDC-AED97A379E86Q34164169-7AD0FB0C-91AF-44B2-BDC1-9AED95EA86D3Q34193265-A24304E7-46CC-4D35-AC88-BE94E224DA9BQ34264615-B08DD57E-9D59-448E-8A35-25341B458368Q34389901-700CC41F-F232-4B0C-BF4C-84DBCB34B0A6Q34398563-151C1964-E035-4343-89AF-12D359CA4FB0Q34409182-C479E1E5-05E5-441F-AC0C-930706C3BCE6Q34457996-40F67B7C-0E43-4A62-B298-A6C72C560DC0Q34781957-EE977251-3558-43A5-AEDF-74AE5EC71F13Q34820590-EE98CE2B-EDBA-4785-B9B0-60CE86F5A055Q34976024-4E9A285C-5F5E-4DB9-B788-E0F1ED024D18Q35038217-8A95A558-D54E-4451-B0D8-F93C0636DF41Q35067373-2CA3BE3C-9CC2-463F-9124-3B8F6DEFE126Q35193261-0AAA961A-9E36-45D7-AD4B-69D013AE5C18Q35567997-C5C2FE59-1A56-4023-BF86-AB6204CCD769Q35785581-65B3B6DA-DB22-434A-BCEE-E5D8A1BCBBAFQ35886800-053E9496-CF83-4F24-A2F3-099CF48DE24BQ36153379-35444743-90D3-4E9B-85CA-3E3F9F48E451Q36378660-E437EBE2-D496-4410-A3CF-2635D8FCD36BQ36391852-D74ED268-BAFB-4D5E-B8AF-FF67BBF5DB2AQ36539048-49E5713C-203F-4211-AA65-7CE7755CC8D4Q36547324-F45A6369-EB37-43E4-BE98-E91D68C7DE24Q36588006-BCB5D84B-A859-482F-852B-8DBCE7FA2CAAQ36606717-6ED6CDEF-40E7-4552-8318-765C27117EB5Q36798576-416DADD8-C91E-4B46-8989-2993810C174BQ36818026-EEE9A7A0-0893-450C-A4E7-3D5B1B2FAF74Q36977584-1D70B10A-8AC1-4699-99BA-00F52F3D2F63
P2860
Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Deficiency of the humoral immu ...... nts immunized at age 6 months.
@en
Deficiency of the humoral immu ...... nts immunized at age 6 months.
@nl
type
label
Deficiency of the humoral immu ...... nts immunized at age 6 months.
@en
Deficiency of the humoral immu ...... nts immunized at age 6 months.
@nl
prefLabel
Deficiency of the humoral immu ...... nts immunized at age 6 months.
@en
Deficiency of the humoral immu ...... nts immunized at age 6 months.
@nl
P2093
P356
P1476
Deficiency of the humoral immu ...... nts immunized at age 6 months.
@en
P2093
P304
P356
10.1001/JAMA.280.6.527
P407
P577
1998-08-01T00:00:00Z